Skye Bioscience, Inc. (SKYE) Executive Compensation
Skye Bioscience, Inc. (SKYE) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: SKYE
CIK: 1516551
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: NV
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
CBIZ CPAs P.C.
Auditor SinceSince 12/31/2025 12:00:00 AM
Lead Engagement PartnerMichael Cohen
Audit LocationMorristown, New Jersey, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| SCHEDULE 13G | 2026-10-14 | — | SCHEDULE 13G Filing | 0001214659-26-012924 | View SEC Doc Filr Page |
| 4 | 2026-09-24 | 2026-09-22 | 4 Filing | 0001598549-26-000015 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-09-24 | — | SCHEDULE 13D/A Filing | 0001873545-26-000009 | View SEC Doc Filr Page |
| 4 | 2026-09-24 | 2026-09-22 | 4 Filing | 0001231919-26-001224 | View SEC Doc Filr Page |
| 4 | 2026-09-18 | 2026-09-16 | 4 Filing | 0001598549-26-000013 | View SEC Doc Filr Page |
| 4 | 2026-09-18 | 2026-09-16 | 4 Filing | 0001231919-26-001197 | View SEC Doc Filr Page |
| DEFA14A | 2026-09-11 | — | DEFA14A | 0001628280-26-061564 | View SEC Doc Filr Page |
| 8-K | 2026-09-11 | 2026-09-08 | 8-K | 0001628280-26-061558 | View SEC Doc Filr Page |
| DEFA14A | 2026-08-24 | — | DEFA14A | 0001628280-26-058615 | View SEC Doc Filr Page |
| 8-K | 2026-08-24 | 2026-08-21 | 8-K | 0001628280-26-058605 | View SEC Doc Filr Page |
| 4 | 2026-08-20 | 2026-08-18 | 4 Filing | 0001598549-26-000005 | View SEC Doc Filr Page |
| 4 | 2026-08-20 | 2026-08-18 | 4 Filing | 0001231919-26-000959 | View SEC Doc Filr Page |
| DEFA14A | 2026-08-20 | — | DEFA14A | 0001628280-26-058121 | View SEC Doc Filr Page |
| 8-K/A | 2026-08-20 | 2026-08-12 | 8-K/A | 0001628280-26-058120 | View SEC Doc Filr Page |
| DEFA14A | 2026-08-19 | — | DEFA14A | 0001628280-26-057806 | View SEC Doc Filr Page |
| 8-K | 2026-08-19 | 2026-08-18 | 8-K | 0001628280-26-057804 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-08-18 | — | SCHEDULE 13D/A Filing | 0001873545-26-000007 | View SEC Doc Filr Page |
| DEFA14A | 2026-08-14 | — | DEFA14A | 0001628280-26-056979 | View SEC Doc Filr Page |
| 10-Q | 2026-08-14 | 2026-06-30 | 10-Q | 0001628280-26-056968 | View SEC Doc Filr Page |
| 8-K | 2026-08-14 | 2026-08-12 | 8-K | 0001628280-26-056966 | View SEC Doc Filr Page |
| 4 | 2026-08-07 | 2026-08-07 | FORM 4 | 0001628280-26-054941 | View SEC Doc Filr Page |
| 8-K | 2026-06-23 | 2026-06-18 | 8-K | 0001628280-26-044747 | View SEC Doc Filr Page |
| 8-K | 2026-05-29 | 2026-05-26 | 8-K | 0001628280-26-039233 | View SEC Doc Filr Page |
| 8-K | 2026-05-15 | 2026-05-13 | 8-K | 0001628280-26-035535 | View SEC Doc Filr Page |
| 10-Q | 2026-05-11 | 2026-03-31 | 10-Q | 0001628280-26-033417 | View SEC Doc Filr Page |